首页 > 最新文献

Leukemia & Lymphoma最新文献

英文 中文
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis. teclistamab治疗复发/难治性多发性骨髓瘤的安全性和有效性:来自多中心、回顾性研究和描述性荟萃分析的结果
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-05 DOI: 10.1080/10428194.2024.2446617
Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Maya C Rosenberg, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S Siegel, Gareth J Morgan, Ruben Niesvizky, Faith E Davies, Noa Biran

Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world. Most patients (87.9%) would not have been eligible for the MajesTEC-1 study due to either disease related factors, patient related comorbidities or socio-economic/geographical factors. Despite these 'less-favorable' characteristics we observed similar efficacy and toxicity to MajesTEC-1. A meta-analysis with six other published real-world series (n = 546) confirmed these results. These data support the significant clinical activity of teclistamab in RRMM and highlights the importance of real-world data to accompany the pivotal trial data to further inform daily clinical practice.

参与临床试验的患者是经过高度筛选的,可能不能代表一般人群。teclistamab (MajesTEC-1)是一种b细胞成熟抗原(BCMA)xCD3双特异性抗体,其关键研究显示,在毒性可接受的复发/难治性多发性骨髓瘤(RRMM)中,teclistamab (MajesTEC-1)的反应率和无进展生存期令人印象深刻。我们对美国四个学术中心的58名患者进行了回顾性研究,以确定这些结果如何转化为现实世界。由于疾病相关因素、患者相关合并症或社会经济/地理因素,大多数患者(87.9%)不符合MajesTEC-1研究的条件。尽管有这些“不太有利”的特征,我们观察到MajesTEC-1的疗效和毒性相似。对其他六个已发表的真实世界系列(n = 546)的荟萃分析证实了这些结果。这些数据支持了teclistamab在RRMM中的显著临床活性,并强调了真实世界数据与关键试验数据的重要性,以进一步为日常临床实践提供信息。
{"title":"Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.","authors":"Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Maya C Rosenberg, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S Siegel, Gareth J Morgan, Ruben Niesvizky, Faith E Davies, Noa Biran","doi":"10.1080/10428194.2024.2446617","DOIUrl":"https://doi.org/10.1080/10428194.2024.2446617","url":null,"abstract":"<p><p>Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world. Most patients (87.9%) would not have been eligible for the MajesTEC-1 study due to either disease related factors, patient related comorbidities or socio-economic/geographical factors. Despite these 'less-favorable' characteristics we observed similar efficacy and toxicity to MajesTEC-1. A meta-analysis with six other published real-world series (n = 546) confirmed these results. These data support the significant clinical activity of teclistamab in RRMM and highlights the importance of real-world data to accompany the pivotal trial data to further inform daily clinical practice.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review. 高负荷滤泡性淋巴瘤治疗进展综述。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-05 DOI: 10.1080/10428194.2024.2447371
Efrat Luttwak, Anita Kumar, Gilles Salles

Follicular lymphoma (FL) represents the second most frequent type of non-Hodgkin lymphoma and the most common indolent histology. The disease course of FL is heterogeneous, likely resulting from diverse molecular and immunological features that drive a broad spectrum of clinical presentations. While some patients with low-volume and asymptomatic disease are suitable for observation, patients with high tumor burden, advanced-stage, or symptomatic disease more often necessitate treatment initiation. The decision to begin therapy is personalized and typically initiated when GELF criteria are met. The introduction of novel agents has modified the treatment landscape for FL, allowing for more personalized strategies based on the specific characteristics of patients and diseases. In this review, we discuss the indications for treatment initiation and optimization, focusing on long-term follow-up of pivotal studies and emerging non-chemotherapy regimens. We further consider effective novel combination regimens and future directions for the evolution of frontline immunotherapy for the treatment of patients with FL.

滤泡性淋巴瘤(FL)是第二常见的非霍奇金淋巴瘤类型,也是最常见的惰性组织学。FL的病程是异质性的,可能是由于不同的分子和免疫学特征导致的,这些特征驱动了广泛的临床表现。部分小体积、无症状的患者适合观察,而肿瘤负荷高、晚期或有症状的患者更需要开始治疗。开始治疗的决定是个性化的,通常在满足GELF标准时开始。新型药物的引入改变了FL的治疗前景,允许基于患者和疾病的特定特征的更个性化的策略。在这篇综述中,我们讨论了治疗开始和优化的适应症,重点是关键研究的长期随访和新兴的非化疗方案。我们进一步考虑有效的新型联合方案和未来发展的前沿免疫疗法的发展方向,以治疗FL患者。
{"title":"Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review.","authors":"Efrat Luttwak, Anita Kumar, Gilles Salles","doi":"10.1080/10428194.2024.2447371","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447371","url":null,"abstract":"<p><p>Follicular lymphoma (FL) represents the second most frequent type of non-Hodgkin lymphoma and the most common indolent histology. The disease course of FL is heterogeneous, likely resulting from diverse molecular and immunological features that drive a broad spectrum of clinical presentations. While some patients with low-volume and asymptomatic disease are suitable for observation, patients with high tumor burden, advanced-stage, or symptomatic disease more often necessitate treatment initiation. The decision to begin therapy is personalized and typically initiated when GELF criteria are met. The introduction of novel agents has modified the treatment landscape for FL, allowing for more personalized strategies based on the specific characteristics of patients and diseases. In this review, we discuss the indications for treatment initiation and optimization, focusing on long-term follow-up of pivotal studies and emerging non-chemotherapy regimens. We further consider effective novel combination regimens and future directions for the evolution of frontline immunotherapy for the treatment of patients with FL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study. 具有心血管危险因素的经典霍奇金淋巴瘤患者的PBVD治疗方案(聚乙二醇化脂质体阿霉素、博来霉素、长春新碱、达卡巴嗪):一项回顾性研究
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-05 DOI: 10.1080/10428194.2024.2447888
Jia Jin, Dan-Dan Meng, Yu Wen, Qun-Ling Zhang, Fang-Fang Lv, Guang-Liang Chen, Xue-Jun Ma, Bao-Hua Yu, Sheng-Jian Zhang, Chang Liu, Zu-Guang Xia

This retrospective study aimed to evaluate the efficacy and safety of PBVD (pegylated liposomal doxorubicin [PLD], bleomycin, vinblastine, and dacarbazine) in the first-line treatment of classical Hodgkin lymphoma (cHL) patients with cardiovascular risk factors. Overall, 84 patients (53 had stage I-II and 31 had stage III-IV disease) received PBVD. The median PLD treatment duration was 16 weeks (interquartile range [IQR]: 8-24) for stage I-II and 24 weeks (IQR: 12-24) for stage III-IV. Among them, 56 (66.7%) received radiotherapy (45 with stage I-II and 11 with stage III-IV disease). Seventy-four (88.1%) patients achieved complete response. At a median follow-up of 49.7 months, 2- and 5-year progression-free survival were both 83.2%, and overall survival was 98.7% and 94.9%. Adverse events occurred in 73.8% of patients, including 7.1% cardiac events. No treatment-related deaths were observed. This approach showed a favorable benefit-to-risk profile in this population.

本回顾性研究旨在评价PBVD(聚乙二醇化脂质体多柔比星[PLD]、博来霉素、长春碱和达卡巴嗪)一线治疗伴有心血管危险因素的经典霍奇金淋巴瘤(cHL)患者的疗效和安全性。总体而言,84例患者(53例为I-II期,31例为III-IV期)接受了PBVD。I-II期PLD治疗的中位持续时间为16周(四分位数间距[IQR]: 8-24), III-IV期为24周(IQR: 12-24)。其中56例(66.7%)接受放疗,其中I-II期45例,III-IV期11例。74例(88.1%)患者获得完全缓解。在49.7个月的中位随访中,2年和5年无进展生存率均为83.2%,总生存率为98.7%和94.9%。不良事件发生率为73.8%,其中心脏事件发生率为7.1%。未观察到与治疗相关的死亡。该方法在该人群中显示出良好的收益-风险比。
{"title":"PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.","authors":"Jia Jin, Dan-Dan Meng, Yu Wen, Qun-Ling Zhang, Fang-Fang Lv, Guang-Liang Chen, Xue-Jun Ma, Bao-Hua Yu, Sheng-Jian Zhang, Chang Liu, Zu-Guang Xia","doi":"10.1080/10428194.2024.2447888","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447888","url":null,"abstract":"<p><p>This retrospective study aimed to evaluate the efficacy and safety of PBVD (pegylated liposomal doxorubicin [PLD], bleomycin, vinblastine, and dacarbazine) in the first-line treatment of classical Hodgkin lymphoma (cHL) patients with cardiovascular risk factors. Overall, 84 patients (53 had stage I-II and 31 had stage III-IV disease) received PBVD. The median PLD treatment duration was 16 weeks (interquartile range [IQR]: 8-24) for stage I-II and 24 weeks (IQR: 12-24) for stage III-IV. Among them, 56 (66.7%) received radiotherapy (45 with stage I-II and 11 with stage III-IV disease). Seventy-four (88.1%) patients achieved complete response. At a median follow-up of 49.7 months, 2- and 5-year progression-free survival were both 83.2%, and overall survival was 98.7% and 94.9%. Adverse events occurred in 73.8% of patients, including 7.1% cardiac events. No treatment-related deaths were observed. This approach showed a favorable benefit-to-risk profile in this population.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salvage therapy for Burkitt lymphoma with glofitamab: a case report. 格非他单抗治疗伯基特淋巴瘤1例。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-03 DOI: 10.1080/10428194.2024.2447882
Pedro Martins Almeida, Thomas Relander, Ola Linden
{"title":"Salvage therapy for Burkitt lymphoma with glofitamab: a case report.","authors":"Pedro Martins Almeida, Thomas Relander, Ola Linden","doi":"10.1080/10428194.2024.2447882","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447882","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia. MYC 在慢性淋巴细胞白血病预后中的多重作用。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-02 DOI: 10.1080/10428194.2024.2447362
Loic Ysebaert, Pierre-Luc Mouchel, Camille Laurent, Anne Quillet-Mary

In this review, we focus on the pro-oncogene MYC, the modes of deregulation in mouse and human B-cells, its undisputable importance in the evaluation of biological prognostication of patients, but also how it impacts on response to modern therapeutics, and how it should be targeted to improve the overall survival of chronic lymphocytic lymphoma (CLL) patients. After an overview of the current understanding of the molecular dysregulation of c-MYC, we will show how CLL, both in its indolent and transformed phases, has developed among other B-cell lymphomas a tight regulation of its expression through the chronic activation of B-Cell Receptors (among others). This is particularly important if one desires to understand the mechanisms at stake in the over-expression of c-MYC especially in the lymph nodes compartment. So doing, we will show how this oncogene orchestrates pivotal cellular functions such as metabolism, drug resistance, proliferation and histologic transformation (Richter syndrome).

在这篇综述中,我们将重点关注促癌基因MYC,小鼠和人类b细胞中的失调模式,其在患者生物学预后评估中的无可争议的重要性,以及它如何影响对现代治疗的反应,以及它应该如何靶向提高慢性淋巴细胞淋巴瘤(CLL)患者的总体生存率。在概述了目前对c-MYC分子失调的理解之后,我们将展示CLL是如何在其惰性期和转化期与其他b细胞淋巴瘤一样,通过b细胞受体的慢性激活而对其表达进行严格调节的。如果想要了解c-MYC过度表达的机制,尤其是在淋巴结室中,这一点尤为重要。这样,我们将展示这种致癌基因如何协调关键的细胞功能,如代谢、耐药性、增殖和组织学转化(Richter综合征)。
{"title":"The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia.","authors":"Loic Ysebaert, Pierre-Luc Mouchel, Camille Laurent, Anne Quillet-Mary","doi":"10.1080/10428194.2024.2447362","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447362","url":null,"abstract":"<p><p>In this review, we focus on the pro-oncogene MYC, the modes of deregulation in mouse and human B-cells, its undisputable importance in the evaluation of biological prognostication of patients, but also how it impacts on response to modern therapeutics, and how it should be targeted to improve the overall survival of chronic lymphocytic lymphoma (CLL) patients. After an overview of the current understanding of the molecular dysregulation of c-MYC, we will show how CLL, both in its indolent and transformed phases, has developed among other B-cell lymphomas a tight regulation of its expression through the chronic activation of B-Cell Receptors (among others). This is particularly important if one desires to understand the mechanisms at stake in the over-expression of c-MYC especially in the lymph nodes compartment. So doing, we will show how this oncogene orchestrates pivotal cellular functions such as metabolism, drug resistance, proliferation and histologic transformation (Richter syndrome).</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives. 重新审视结节淋巴细胞为主的霍奇金淋巴瘤:当前的管理策略和未来的展望。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-02 DOI: 10.1080/10428194.2024.2447886
Dennis A Eichenauer, Peter Borchmann

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity accounting for ≈5% of all Hodgkin lymphoma (HL) cases. As some characteristics of NLPHL resemble B-cell non-Hodgkin lymphoma (B-NHL), nodular lymphocyte-predominant B-cell lymphoma has been proposed as alternative name. Unlike classical HL (cHL), NLPHL is mostly diagnosed in early stages. The clinical course is usually indolent. Overall, NLPHL patients have an excellent prognosis and the majority experiences long-term survival. Except for stage IA disease which is sufficiently treated with radiotherapy alone, treatment of newly diagnosed NLPHL is often very similar to cHL. However, activity has also been demonstrated for rituximab-containing protocols applied in B-NHL. Second-line treatment is chosen individually and mostly less intensive than in cHL. Chimeric antigen receptor T-cell therapy and bispecific antibodies may be part of future treatment strategies for NLPHL. This review aims at summarizing recent data on treatment approaches and discussing future perspectives in NLPHL.

结节性淋巴细胞主导型霍奇金淋巴瘤(NLPHL)是一种罕见的淋巴瘤,约占所有霍奇金淋巴瘤(HL)病例的5%。由于NLPHL的某些特征类似于b细胞非霍奇金淋巴瘤(B-NHL),因此有人建议将结节性淋巴细胞为主的b细胞淋巴瘤作为替代名称。与经典HL (cHL)不同,NLPHL大多在早期诊断。临床过程通常不痛不痒。总体而言,NLPHL患者预后良好,大多数患者长期生存。除了仅用放射治疗就能充分治疗的IA期疾病外,新诊断的NLPHL的治疗通常与cHL非常相似。然而,含有利妥昔单抗的方案也被证明适用于B-NHL。二线治疗是单独选择的,其强度大多低于cHL。嵌合抗原受体t细胞疗法和双特异性抗体可能是未来NLPHL治疗策略的一部分。这篇综述旨在总结最近关于NLPHL治疗方法的数据,并讨论未来的前景。
{"title":"Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.","authors":"Dennis A Eichenauer, Peter Borchmann","doi":"10.1080/10428194.2024.2447886","DOIUrl":"https://doi.org/10.1080/10428194.2024.2447886","url":null,"abstract":"<p><p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity accounting for ≈5% of all Hodgkin lymphoma (HL) cases. As some characteristics of NLPHL resemble B-cell non-Hodgkin lymphoma (B-NHL), nodular lymphocyte-predominant B-cell lymphoma has been proposed as alternative name. Unlike classical HL (cHL), NLPHL is mostly diagnosed in early stages. The clinical course is usually indolent. Overall, NLPHL patients have an excellent prognosis and the majority experiences long-term survival. Except for stage IA disease which is sufficiently treated with radiotherapy alone, treatment of newly diagnosed NLPHL is often very similar to cHL. However, activity has also been demonstrated for rituximab-containing protocols applied in B-NHL. Second-line treatment is chosen individually and mostly less intensive than in cHL. Chimeric antigen receptor T-cell therapy and bispecific antibodies may be part of future treatment strategies for NLPHL. This review aims at summarizing recent data on treatment approaches and discussing future perspectives in NLPHL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia. 成人急性髓性白血病RAS通路改变的分子、临床和预后意义。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-02 DOI: 10.1080/10428194.2024.2441855
Fenghong Zhang, Yizi Liu, Yiyan Zhu, Qingyuan Wang, Xiangyu Zhao, Qian Wang, Yu Chen, Suning Chen

Alterations in the RAS pathway underscore the pathogenic complexity of acute myeloid leukemia (AML), yet the full spectrum, including CBL, NF1, PTPN11, KRAS, and NRAS, remains to be fully elucidated. In this retrospective study of 735 adult AML patients, the incidence of RAS pathway alterations was 32.4%, each with distinct clinical characteristics. Venetoclax combined with hypomethylating agents (VEN + HMA) did not significantly improve response rates compared to intensive chemotherapy (IC) group. In the IC group, PTPN11 mutations in the N-SH2 domain showed a trend toward poorer prognosis, though not statistically significant in multivariate analysis, while NRAS mutations correlated with improved outcomes. In the VEN + HMA group, PTPN11 mutations in the N-SH2 domain emerged as an independent adverse prognostic marker. NRAS or KRAS mutations showed no survival advantage compared to wild-type, aligning with their intermediate-risk classification in the 2024 ELN guidelines. These findings emphasize the need for treatment-specific risk stratification for RAS pathway mutations in AML.

RAS通路的改变强调了急性髓性白血病(AML)的致病复杂性,但包括CBL、NF1、PTPN11、KRAS和NRAS在内的全谱仍有待完全阐明。本研究对735例成人AML患者进行回顾性研究,RAS通路改变发生率为32.4%,各有不同的临床特点。与强化化疗(IC)组相比,Venetoclax联合低甲基化药物(VEN + HMA)没有显著提高缓解率。在IC组中,N-SH2结构域PTPN11突变表现出预后较差的趋势,但在多变量分析中没有统计学意义,而NRAS突变与预后改善相关。在VEN + HMA组中,N-SH2结构域的PTPN11突变成为一个独立的不良预后标志物。与野生型相比,NRAS或KRAS突变没有表现出生存优势,符合2024年ELN指南中的中等风险分类。这些发现强调了对AML中RAS通路突变进行治疗特异性风险分层的必要性。
{"title":"Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.","authors":"Fenghong Zhang, Yizi Liu, Yiyan Zhu, Qingyuan Wang, Xiangyu Zhao, Qian Wang, Yu Chen, Suning Chen","doi":"10.1080/10428194.2024.2441855","DOIUrl":"https://doi.org/10.1080/10428194.2024.2441855","url":null,"abstract":"<p><p>Alterations in the RAS pathway underscore the pathogenic complexity of acute myeloid leukemia (AML), yet the full spectrum, including <i>CBL</i>, <i>NF1</i>, <i>PTPN11</i>, <i>KRAS</i>, and <i>NRAS</i>, remains to be fully elucidated. In this retrospective study of 735 adult AML patients, the incidence of RAS pathway alterations was 32.4%, each with distinct clinical characteristics. Venetoclax combined with hypomethylating agents (VEN + HMA) did not significantly improve response rates compared to intensive chemotherapy (IC) group. In the IC group, <i>PTPN11</i> mutations in the N-SH2 domain showed a trend toward poorer prognosis, though not statistically significant in multivariate analysis, while <i>NRAS</i> mutations correlated with improved outcomes. In the VEN + HMA group, <i>PTPN11</i> mutations in the N-SH2 domain emerged as an independent adverse prognostic marker. <i>NRAS</i> or <i>KRAS</i> mutations showed no survival advantage compared to wild-type, aligning with their intermediate-risk classification in the 2024 ELN guidelines. These findings emphasize the need for treatment-specific risk stratification for RAS pathway mutations in AML.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab. 一名接受莫苏尼珠单抗治疗的重度预处理淋巴瘤患者持续感染 parvovirus B19。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-09-23 DOI: 10.1080/10428194.2024.2404246
Wolfgang Füreder, Cathrin Skrabs, Selma Tobudic
{"title":"Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab.","authors":"Wolfgang Füreder, Cathrin Skrabs, Selma Tobudic","doi":"10.1080/10428194.2024.2404246","DOIUrl":"10.1080/10428194.2024.2404246","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"163-165"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enasidenib in relapsed aggressive systemic mastocytosis with IDH2 mutation. 依那西尼治疗IDH2突变的复发侵袭性系统性肥大细胞增多症
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-10-22 DOI: 10.1080/10428194.2024.2410942
Alejandro Del Rio Verduzco, Ali Al Darobi, Alex Heimbigner, Hayley Heers, Matthew Ulrickson
{"title":"Enasidenib in relapsed aggressive systemic mastocytosis with IDH2 mutation.","authors":"Alejandro Del Rio Verduzco, Ali Al Darobi, Alex Heimbigner, Hayley Heers, Matthew Ulrickson","doi":"10.1080/10428194.2024.2410942","DOIUrl":"10.1080/10428194.2024.2410942","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"170-173"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD1a + histiocytoses in primary myelofibrosis patients: just a casual association? A case report and systematic review of the literature. 原发性骨髓纤维化患者的CD1a +组织细胞增多:只是偶然的关联?一份病例报告及文献系统回顾。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-02 DOI: 10.1080/10428194.2024.2404247
Arturo Bonometti, Alexandar Tzankov, Ilaria Alborelli, Philip Went, Stefan Dirnhofer
{"title":"CD1a + histiocytoses in primary myelofibrosis patients: just a casual association? A case report and systematic review of the literature.","authors":"Arturo Bonometti, Alexandar Tzankov, Ilaria Alborelli, Philip Went, Stefan Dirnhofer","doi":"10.1080/10428194.2024.2404247","DOIUrl":"https://doi.org/10.1080/10428194.2024.2404247","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":"66 1","pages":"139-146"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Leukemia & Lymphoma
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1